PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
60.35%
G&A change of 60.35% versus flat Biotechnology overhead. Walter Schloss would verify efficiency.
No Data
No Data available this quarter, please select a different quarter.
117.22%
Other expenses change of 117.22% versus flat Biotechnology costs. Walter Schloss would verify efficiency.
89.95%
Operating expenses change of 89.95% versus flat Biotechnology costs. Walter Schloss would verify control.
89.95%
Total costs change of 89.95% versus flat Biotechnology costs. Walter Schloss would verify control.
-4.24%
Interest expense reduction while Biotechnology median is 0.00%. Seth Klarman would investigate advantages.
100.53%
D&A change of 100.53% versus flat Biotechnology D&A. Walter Schloss would verify adequacy.
79.29%
EBITDA change of 79.29% versus flat Biotechnology. Walter Schloss would verify quality.
No Data
No Data available this quarter, please select a different quarter.
-95.43%
Operating income decline while Biotechnology median is 0.00%. Seth Klarman would investigate causes.
No Data
No Data available this quarter, please select a different quarter.
-104.55%
Other expenses reduction while Biotechnology median is 0.00%. Seth Klarman would investigate advantages.
-100.00%
Pre-tax income decline while Biotechnology median is 0.00%. Seth Klarman would investigate causes.
No Data
No Data available this quarter, please select a different quarter.
-15.40%
Tax expense reduction while Biotechnology median is 0.00%. Seth Klarman would investigate advantages.
-134.36%
Net income decline while Biotechnology median is 0.00%. Seth Klarman would investigate causes.
No Data
No Data available this quarter, please select a different quarter.
-134.21%
EPS decline while Biotechnology median is 0.00%. Seth Klarman would investigate causes.
-134.21%
Diluted EPS decline while Biotechnology median is 0.00%. Seth Klarman would investigate causes.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.